Skip to main content
. 2024 Aug 10;10(16):e35847. doi: 10.1016/j.heliyon.2024.e35847

Fig. 2.

Fig. 2

Possible mechanisms of ABT-199 synergy with gilteritinib in AML1-ETO-positive AML. (A) The ZIP scores of SKNO-1 and Kasumi-1 were subjected to treatment with ABT-199 and gilteritinib for 24h and 72h. (B) The protein expression of BCL-2, MCL-1， BCL-XL, and β-actin in SKNO-1 and Kasumi-1 cell lines treated with ABT-199 and/or gilteritinib for 24h and 72h. (C) Viability of SKNO-1 and Kasumi-1 after treatment with DMSO, ABT-199 (ABT), gilteritinib (Gilt), or a combination of the two drugs (GA) in the absence or presence of ISRIB for 24h and 72h. (D) MCL-1, BCL-XL, and α-actinin protein expression of SKNO-1 and Kasumi-1 after treatment with DMSO, ABT-199, gilteritinib, or a combination of the two drugs in the absence or presence of ISRIB for 72h. ABT: ABT-199; Gilt: gilteritinib; GA: ABT-199 + gilteritinib.